A different study, BOLERO-3 [43], reported that the addition of everolimus to trastuzumab plus vinorelbine significantly prolonged PFS in patients with trastuzumab-resistant and taxane-pretreated, HER-2-positive, advanced breast carcinoma. Here, ERBB2 is linked to breast carcinoma.